Skip to main content
Pentixapharm Holding AG logo

Pentixapharm Holding AG — Investor Relations & Filings

Ticker · PTP ISIN · DE000A40AEG0 LEI · 3912005VBOVXNDXEQZ36 F Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country DE Germany
Listing F PTP

About Pentixapharm Holding AG

https://www.pentixapharm.com/

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Recent filings

Filing Released Lang Actions
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
Regulatory Filings Classification · 87% confidence The document is a corporate press release announcing submission of an IND application to the FDA for a Phase 3 clinical trial. It does not contain financial results, director changes, voting results, or substantive financial statements, nor is it a presentation or investor material. It is a regulatory announcement/fallback filing. Therefore, it best fits into the “Regulatory Filings” category.
2026-05-11 English
Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of Pentixapharm's first quarter 2026 financial results, including financial highlights, business updates, regulatory progress, and leadership changes. It contains substantive financial data such as net loss, EBITDA, cash flow, and assets for the quarter ended March 31, 2026. The document also discusses operational progress and strategic outlook, typical of an interim financial report. It explicitly states that the full interim financial statements are available on the company's website, indicating this document itself is a comprehensive quarterly report rather than just an announcement of report availability. The length of the document (over 10,000 characters) and the inclusion of detailed financial and operational information confirm it is an Interim / Quarterly Report (IR).
2026-05-07 English
Q1 statement / Q1 financial report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q1 REPORT 2026' and contains detailed financial statements and management discussion for the first quarter of 2026. It includes an Interim Group Management Report with earnings performance, net assets and financial position, outlook, risks and opportunities, and additional disclosures. It also contains interim consolidated financial statements such as the statement of comprehensive income, balance sheet, cash flow statement, and statement of changes in equity. The presence of actual financial data and comprehensive analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). Q1 2026
2026-05-07 English
Annual financial report 2025
Annual Report Classification · 95% confidence The text is the complete annual report for fiscal year 2025, including a detailed table of contents, letter to shareholders, combined management report, consolidated financial statements with notes, independent auditor’s report, and other disclosures. It clearly constitutes the full yearly report covering company activity and full financial performance, matching the Annual Report definition. It is not merely an announcement of publication. FY 2025
2026-04-28 English
Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
Board/Management Information Classification · 94% confidence The document is a corporate press release announcing the appointment of Erik Merten to the Executive Board of Pentixapharm Holding AG. It specifically relates to a change in senior management (board-level appointment). This clearly falls under ‘Board/Management Information’ (MANG). It is not a full financial report, earnings release, or regulatory filing, but rather a personnel announcement.
2026-03-31 English
Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3580 characters) informing stakeholders that Pentixapharm Holding AG will publish its 2025 financial report on a future date (March 26, 2026) and providing details for an upcoming conference call. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2026-03-19 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.